536 related articles for article (PubMed ID: 25707991)
1. Fyn inhibition rescues established memory and synapse loss in Alzheimer mice.
Kaufman AC; Salazar SV; Haas LT; Yang J; Kostylev MA; Jeng AT; Robinson SA; Gunther EC; van Dyck CH; Nygaard HB; Strittmatter SM
Ann Neurol; 2015 Jun; 77(6):953-71. PubMed ID: 25707991
[TBL] [Abstract][Full Text] [Related]
2. The Fyn kinase inhibitor, AZD0530, suppresses mouse alcohol self-administration and seeking.
Morisot N; Berger AL; Phamluong K; Cross A; Ron D
Addict Biol; 2019 Nov; 24(6):1227-1234. PubMed ID: 30536923
[TBL] [Abstract][Full Text] [Related]
3. Disease-modifying benefit of Fyn blockade persists after washout in mouse Alzheimer's model.
Smith LM; Zhu R; Strittmatter SM
Neuropharmacology; 2018 Mar; 130():54-61. PubMed ID: 29191754
[TBL] [Abstract][Full Text] [Related]
4. Panaxadiol inhibits synaptic dysfunction in Alzheimer's disease and targets the Fyn protein in APP/PS1 mice and APP-SH-SY5Y cells.
Liang X; Yao Y; Lin Y; Kong L; Xiao H; Shi Y; Yang J
Life Sci; 2019 Mar; 221():35-46. PubMed ID: 30735733
[TBL] [Abstract][Full Text] [Related]
5. In Vivo Synaptic Density Imaging with
Toyonaga T; Smith LM; Finnema SJ; Gallezot JD; Naganawa M; Bini J; Mulnix T; Cai Z; Ropchan J; Huang Y; Strittmatter SM; Carson RE
J Nucl Med; 2019 Dec; 60(12):1780-1786. PubMed ID: 31101744
[No Abstract] [Full Text] [Related]
6. Targeting Fyn Kinase in Alzheimer's Disease.
Nygaard HB
Biol Psychiatry; 2018 Feb; 83(4):369-376. PubMed ID: 28709498
[TBL] [Abstract][Full Text] [Related]
7. Fyn kinase inhibition reduces protein aggregation, increases synapse density and improves memory in transgenic and traumatic Tauopathy.
Tang SJ; Fesharaki-Zadeh A; Takahashi H; Nies SH; Smith LM; Luo A; Chyung A; Chiasseu M; Strittmatter SM
Acta Neuropathol Commun; 2020 Jul; 8(1):96. PubMed ID: 32611392
[TBL] [Abstract][Full Text] [Related]
8. Anti-PrP
Cox TO; Gunther EC; Brody AH; Chiasseu MT; Stoner A; Smith LM; Haas LT; Hammersley J; Rees G; Dosanjh B; Groves M; Gardener M; Dobson C; Vaughan T; Chessell I; Billinton A; Strittmatter SM
Ann Clin Transl Neurol; 2019 Mar; 6(3):554-574. PubMed ID: 30911579
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of disease-modifying effect of saracatinib (AZD0530), a Src/Fyn tyrosine kinase inhibitor, in the rat kainate model of temporal lobe epilepsy.
Sharma S; Carlson S; Gregory-Flores A; Hinojo-Perez A; Olson A; Thippeswamy T
Neurobiol Dis; 2021 Aug; 156():105410. PubMed ID: 34087381
[TBL] [Abstract][Full Text] [Related]
10. Alzheimer's Disease Risk Factor Pyk2 Mediates Amyloid-β-Induced Synaptic Dysfunction and Loss.
Salazar SV; Cox TO; Lee S; Brody AH; Chyung AS; Haas LT; Strittmatter SM
J Neurosci; 2019 Jan; 39(4):758-772. PubMed ID: 30518596
[TBL] [Abstract][Full Text] [Related]
11. The Kinase Fyn As a Novel Intermediate in L-DOPA-Induced Dyskinesia in Parkinson's Disease.
Sanz-Blasco S; Bordone MP; Damianich A; Gomez G; Bernardi MA; Isaja L; Taravini IR; Hanger DP; Avale ME; Gershanik OS; Ferrario JE
Mol Neurobiol; 2018 Jun; 55(6):5125-5136. PubMed ID: 28840468
[TBL] [Abstract][Full Text] [Related]
12. The small molecules AZD0530 and dasatinib inhibit dengue virus RNA replication via Fyn kinase.
de Wispelaere M; LaCroix AJ; Yang PL
J Virol; 2013 Jul; 87(13):7367-81. PubMed ID: 23616652
[TBL] [Abstract][Full Text] [Related]
13. The flavonoid baicalein rescues synaptic plasticity and memory deficits in a mouse model of Alzheimer's disease.
Gu XH; Xu LJ; Liu ZQ; Wei B; Yang YJ; Xu GG; Yin XP; Wang W
Behav Brain Res; 2016 Sep; 311():309-321. PubMed ID: 27233830
[TBL] [Abstract][Full Text] [Related]
14. Isoorientin, a GSK-3β inhibitor, rescues synaptic dysfunction, spatial memory deficits and attenuates pathological progression in APP/PS1 model mice.
Tan X; Liang Z; Li Y; Zhi Y; Yi L; Bai S; Forest KH; Nichols RA; Dong Y; Li QX
Behav Brain Res; 2021 Feb; 398():112968. PubMed ID: 33069740
[TBL] [Abstract][Full Text] [Related]
15. Pyk2 is a Novel Tau Tyrosine Kinase that is Regulated by the Tyrosine Kinase Fyn.
Li C; Götz J
J Alzheimers Dis; 2018; 64(1):205-221. PubMed ID: 29782321
[TBL] [Abstract][Full Text] [Related]
16. Current Research Therapeutic Strategies for Alzheimer's Disease Treatment.
Folch J; Petrov D; Ettcheto M; Abad S; Sánchez-López E; García ML; Olloquequi J; Beas-Zarate C; Auladell C; Camins A
Neural Plast; 2016; 2016():8501693. PubMed ID: 26881137
[TBL] [Abstract][Full Text] [Related]
17. Fuzhisan ameliorates Aβ production and tau phosphorylation in hippocampal of 11month old APP/PS1 transgenic mice: A Western blot study.
Zhang ZX; Zhao RP; Wang DS; Wang AN
Exp Gerontol; 2016 Nov; 84():88-95. PubMed ID: 27612601
[TBL] [Abstract][Full Text] [Related]
18. Fyn knock-down increases Aβ, decreases phospho-tau, and worsens spatial learning in 3×Tg-AD mice.
Minami SS; Clifford TG; Hoe HS; Matsuoka Y; Rebeck GW
Neurobiol Aging; 2012 Apr; 33(4):825.e15-24. PubMed ID: 21741124
[TBL] [Abstract][Full Text] [Related]
19. Dihydromyricetin inhibits microglial activation and neuroinflammation by suppressing NLRP3 inflammasome activation in APP/PS1 transgenic mice.
Feng J; Wang JX; Du YH; Liu Y; Zhang W; Chen JF; Liu YJ; Zheng M; Wang KJ; He GQ
CNS Neurosci Ther; 2018 Dec; 24(12):1207-1218. PubMed ID: 29869390
[TBL] [Abstract][Full Text] [Related]
20. Tanshinone IIA regulates glycogen synthase kinase-3β-related signaling pathway and ameliorates memory impairment in APP/PS1 transgenic mice.
Peng X; Chen L; Wang Z; He Y; Ruganzu JB; Guo H; Zhang X; Ji S; Zheng L; Yang W
Eur J Pharmacol; 2022 Mar; 918():174772. PubMed ID: 35090935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
